Fresenius Kabi says the acceptance by the European Medicines Agency of the firm’s marketing authorization application for a biosimilar version of Neulasta represents a “milestone” for the company as it continues to work towards a launch in 2021 in both the EU and US.
Fresenius Kabi Files EU Pegfilgrastim
‘Milestone’ Biosimilar Submission Comes Ahead Of Planned Launch In 2021
Fresenius Kabi’s biosimilar pegfilgrastim rival to Neulasta has been accepted for review by the European Medicines Agency. The firm believes the “milestone” application will pave the way for a 2021 launch.
